Novartis Ag ADR (NVS)

$106.83 -2.12 (-1.95%)
Market Cap 229.62B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 13.79
Forward PE 13.15
Profit Margin 23.09%
Debt to Equity Ratio 0.77
Volume 1,750,825
Avg Vol 2,445,580
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 3%
Beta 0.60
Analysts Sell
Price Target $118.00

Latest News on NVS

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

May 12, 2025, 3:54 PM EDT - 1 day ago

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

ABBV GSK JNJ LLY MRK NVO PFE

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

May 12, 2025, 12:36 PM EDT - 1 day ago

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

ABBV AMGN AZN GILD GSK JNJ LLY

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

May 12, 2025, 12:30 PM EDT - 1 day ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BIIB BMY GILD JNJ LLY

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

May 12, 2025, 5:30 AM EDT - 1 day ago

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

ABBV AMGN AZN GSK JNJ LLY MRK

Novartis to keep making malaria drugs if orders dry up amid aid cuts

May 12, 2025, 3:19 AM EDT - 1 day ago

Novartis to keep making malaria drugs if orders dry up amid aid cuts

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

May 9, 2025, 4:51 PM EDT - 4 days ago

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

JNJ NVO SNY

Pressure is still on the pharma sector, says Mizuho's Jared Holz

May 8, 2025, 7:23 PM EDT - 5 days ago

Pressure is still on the pharma sector, says Mizuho's Jared Holz

ABBV AMGN BMY GILD JNJ LLY MRK

BioNTech says Novartis executive Zapata-Gomez to become CFO

May 5, 2025, 6:34 AM EDT - 8 days ago

BioNTech says Novartis executive Zapata-Gomez to become CFO

BNTX

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 12 days ago

Final Trade: NVS, XLU and SMMT

SMMT XLU

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

Apr 30, 2025, 4:12 PM EDT - 13 days ago

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

ABBV ABT DXCM GSK JNJ LLY MRK

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

Apr 30, 2025, 12:24 PM EDT - 13 days ago

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

RGLS

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Apr 30, 2025, 11:22 AM EDT - 13 days ago

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

RGLS

Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed

Apr 30, 2025, 9:46 AM EDT - 13 days ago

Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed

Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis

Apr 30, 2025, 9:38 AM EDT - 13 days ago

Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis

Novartis to Acquire Regulus in $1.7 Billion Deal

Apr 30, 2025, 7:50 AM EDT - 13 days ago

Novartis to Acquire Regulus in $1.7 Billion Deal

RGLS

Novartis to buy Regulus Therapeutics for up to $1.7 billion

Apr 30, 2025, 7:25 AM EDT - 13 days ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

RGLS

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Apr 30, 2025, 7:10 AM EDT - 13 days ago

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

RGLS

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Apr 30, 2025, 7:00 AM EDT - 13 days ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

RGLS

We have put ourselves in the right position to manage tariffs: Novartis CEO

Apr 29, 2025, 4:05 PM EDT - 14 days ago

We have put ourselves in the right position to manage tariffs: Novartis CEO

Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry

Apr 29, 2025, 2:15 PM EDT - 14 days ago

Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry

Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 2:09 PM EDT - 14 days ago

Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well

Apr 29, 2025, 12:19 PM EDT - 14 days ago

Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well

Pharma firms maastraz

Apr 29, 2025, 12:06 PM EDT - 14 days ago

Pharma firms maastraz

AZN GSK NVO

Novartis posts better-than-expected first-quarter sales, raises full-year guidance

Apr 29, 2025, 4:22 AM EDT - 14 days ago

Novartis posts better-than-expected first-quarter sales, raises full-year guidance

Novartis Lifts Guidance After Profit, Sales Top Views

Apr 29, 2025, 1:27 AM EDT - 15 days ago

Novartis Lifts Guidance After Profit, Sales Top Views

Novartis more upbeat on 2025 guidance after strong Q1 momentum

Apr 29, 2025, 1:12 AM EDT - 15 days ago

Novartis more upbeat on 2025 guidance after strong Q1 momentum

Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs

Apr 23, 2025, 2:44 AM EDT - 21 days ago

Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs

SNY

LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed

Apr 21, 2025, 9:00 AM EDT - 22 days ago

LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed

ABBV AMGN AZN BMY GSK JNJ LLY

Trump Says Pharmaceutical Tariffs Coming in Near Future

Apr 14, 2025, 2:03 PM EDT - 4 weeks ago

Trump Says Pharmaceutical Tariffs Coming in Near Future

ABBV AMGN AZN BMY GSK IBB JNJ

Trump says US pharma tariffs coming in not-too-distant future

Apr 14, 2025, 12:26 PM EDT - 4 weeks ago

Trump says US pharma tariffs coming in not-too-distant future

ABBV AMGN AZN BMY GSK JNJ LLY

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

Apr 11, 2025, 10:30 AM EDT - 4 weeks ago

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

ABBV AMGN AZN BMY GSK IBB JNJ

Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs

Apr 10, 2025, 6:11 PM EDT - 4 weeks ago

Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs

Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats

Apr 10, 2025, 1:33 PM EDT - 4 weeks ago

Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats

Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback

Apr 10, 2025, 4:45 AM EDT - 4 weeks ago

Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback

ABBV AMGN AZN BMY GSK JNJ LLY

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Apr 9, 2025, 6:32 PM EDT - 4 weeks ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

Apr 9, 2025, 3:59 PM EDT - 4 weeks ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Explainer: Prescription drugs become a target in Trump's trade war

Apr 9, 2025, 2:27 PM EDT - 4 weeks ago

Explainer: Prescription drugs become a target in Trump's trade war

ABBV AMGN AZN BMY GSK IBB JNJ

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

Apr 9, 2025, 1:06 PM EDT - 4 weeks ago

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

ABBV AMGN AZN BMY GSK IBB JNJ

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Apr 9, 2025, 11:53 AM EDT - 4 weeks ago

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

ABBV AMGN AZN BMY GSK JNJ LLY

Global pharma shares plunge as Trump doubles down on tariff threat

Apr 9, 2025, 9:50 AM EDT - 4 weeks ago

Global pharma shares plunge as Trump doubles down on tariff threat

ABBV AMGN AZN GSK LLY MRK PFE

Trump teases targeted tariffs on overseas drug manufacturers

Apr 8, 2025, 11:32 PM EDT - 5 weeks ago

Trump teases targeted tariffs on overseas drug manufacturers

AZN GSK IHE PJP SNY XPH

Novartis After Sandoz: The Business Without Generics

Apr 6, 2025, 6:38 AM EDT - 5 weeks ago

Novartis After Sandoz: The Business Without Generics

Pharma tariff relief likely short-lived with sector-specific duties on the horizon

Apr 3, 2025, 6:25 AM EDT - 5 weeks ago

Pharma tariff relief likely short-lived with sector-specific duties on the horizon

AZN NVO

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Apr 2, 2025, 8:29 PM EDT - 5 weeks ago

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Pharma tariffs the 'number one question' on investors' minds, Barclays says

Mar 31, 2025, 2:30 PM EDT - 6 weeks ago

Pharma tariffs the 'number one question' on investors' minds, Barclays says

AZN GSK NVO

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

Mar 31, 2025, 1:00 AM EDT - 6 weeks ago

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Mar 28, 2025, 12:52 PM EDT - 6 weeks ago

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Mar 25, 2025, 2:15 AM EDT - 7 weeks ago

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Mar 20, 2025, 7:37 PM EDT - 7 weeks ago

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Mar 20, 2025, 7:11 PM EDT - 7 weeks ago

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)